Background and Rationale

InclusiVibe Foundation exists because the evidence demands it.

The diagnostic experiences of people with complex neuro-connective tissue conditions are not anecdotal. They are documented, peer-reviewed, and reproducible across international datasets. This page presents that evidence — the research that grounds our programs, informs our advocacy, and makes the case that what this community has lived is a systemic failure, not a personal one.

The scale of diagnostic delay

A 2025 global survey of 3,906 participants with hEDS and HSD found an average diagnostic delay of 22.1 years between symptom onset and confirmed diagnosis. Participants received their diagnosis at an average age of 31.4 years, meaning symptoms began in childhood or early adolescence for the majority and remained unresolved for over two decades.[1]

A 2023 study of 505 clinically confirmed hEDS patients found an average of 10.45 alternative diagnoses received prior to correct diagnosis. Diagnoses most frequently rejected as inaccurate: functional neurological disorder, multiple sclerosis, and fibromyalgia. Average time to correct diagnosis: 10.39 years.[2]

For context across the rare disease landscape: a 2009 survey of 12,000 patients by EURORDIS found an average diagnostic delay of 14 years across rare conditions. The hEDS population significantly exceeds this already-alarming baseline.[3]

Psychiatric misattribution and its consequences

A 2025 retrospective chart review of 429 hEDS patients found that 94.4% had received an incorrect psychiatric diagnosis from a non-psychiatrist before receiving their hEDS diagnosis. 88% reported that providers told them their symptoms were fabricated or exaggerated.[4]

This pattern — psychiatric attribution before structural investigation — is the central mechanism InclusiVibe Foundation documents. It is not an isolated clinical error. It is a reproducible systemic pattern across provider types, healthcare systems, and geographic regions. The consequences are measurable: delayed access to structural evaluation, inappropriate treatment, lasting barriers to specialist referral, denial of equipment and disability accommodations, and in some cases permanent functional loss from conditions that progressed during the diagnostic delay.

Reference:

1. Daylor V, Griggs M, Weintraub A, et al. Defining the chronic complexities of hEDS and HSD: a global survey of diagnostic challenges, life-long comorbidities, and unmet needs. J Clin Med. 2025;14(16):5636. doi:10.3390/jcm14165636

2. Halverson CME, Cao S, Perkins SM, Francomano CA. Comorbidity, misdiagnoses, and the diagnostic odyssey in patients with hypermobile Ehlers-Danlos Syndrome. Genetics in Medicine Open. 2023;1:100812. doi:10.1016/j.gimo.2023.100812

3. EURORDIS — Rare Diseases Europe. Voice of 12,000 Patients: Experiences and Expectations of Rare Disease Patients on Diagnosis and Research. 2009.

 4. Lee C, Chopra P. The incidence of misdiagnosis in patients with Ehlers-Danlos Syndrome. Children (Basel). 2025;12(6):698. doi:10.3390/children12060698

For donations, collaboration inquiries, & sponsorships: